- Home
- IRON vs CRAI Comparison
IRON vs CRAI Comparison
Compare IRON & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- CRAI
- Stock Information
- Founded
- IRON 2017
- CRAI 1965
- Country
- IRON United States
- CRAI United States
- Employees
- IRON N/A
- CRAI N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- CRAI Other Consumer Services
- Sector
- IRON Health Care
- CRAI Consumer Discretionary
- Exchange
- IRON Nasdaq
- CRAI Nasdaq
- Market Cap
- IRON 1.4B
- CRAI 1.3B
- IPO Year
- IRON N/A
- CRAI 1998
- Fundamental
- Price
- IRON $46.68
- CRAI $190.05
- Analyst Decision
- IRON Strong Buy
- CRAI Buy
- Analyst Count
- IRON 9
- CRAI 1
- Target Price
- IRON $93.89
- CRAI $228.00
- AVG Volume (30 Days)
- IRON 354.8K
- CRAI 70.6K
- Earning Date
- IRON 05-07-2025
- CRAI 05-01-2025
- Dividend Yield
- IRON N/A
- CRAI 1.03%
- EPS Growth
- IRON N/A
- CRAI 21.18
- EPS
- IRON N/A
- CRAI 7.40
- Revenue
- IRON N/A
- CRAI $697,476,000.00
- Revenue This Year
- IRON N/A
- CRAI $7.45
- Revenue Next Year
- IRON N/A
- CRAI $4.54
- P/E Ratio
- IRON N/A
- CRAI $25.67
- Revenue Growth
- IRON N/A
- CRAI 8.49
- 52 Week Low
- IRON $30.82
- CRAI $133.54
- 52 Week High
- IRON $68.73
- CRAI $214.01
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- CRAI 60.18
- Support Level
- IRON $44.85
- CRAI $184.11
- Resistance Level
- IRON $47.36
- CRAI $191.44
- Average True Range (ATR)
- IRON 2.23
- CRAI 4.67
- MACD
- IRON -0.12
- CRAI -0.26
- Stochastic Oscillator
- IRON 37.58
- CRAI 67.29
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About CRAI CRA International Inc.
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.